gdc
Multiple Myeloma

New Myeloma Medicines

Yelak Biru offers his feedback on the new medications that were approved in 2015, and the importance of knowing how these medicines will be used and which types of patients will be treated with them.
Video Library – February 4, 2016
Yelak Biru
Patient, North Texas Myeloma Support Group Leader; Member, International Myeloma Foundation; Advisory Committee Chair, Global Myeloma Action Network

2015 has actually been a banner year for myeloma treatment since I was diagnosed 20 years ago at age 25. There were four different drugs that were approved for myeloma, two of them first in class. Three of them were actually approved in the same month, in November.

This is really great for myeloma patients, for us to be able to have options. We also at the same time need to know a few things about these drugs. One is, what is their indication?

By the indication, I mean are they going to be used in first line treatment or are they going to be used in relapse and refractory settings. We also need to know how these drugs are being administered. Are they given over IV over several hours, or are they taken at home orally.

Those are I think the two major things we need to know about these drugs. I think we also need to be part of online organizations and social medias to also understand the side effects of these drugs, so when we encounter them, we already know what the side effects are and if they are common or uncommon from a side effect perspective.

I think during ASH meeting here, the doctors are also indicating that a three drug combo is better than a two drug combo. We also need to understand what the side effects of not only these approved drugs are, but the side effects of the drugs that they will be combined with, so we are fully aware of and understand the drugs that we are taking as part of our future treatment.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country